BS_5PJCHF6V
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 36.563731931668855
- age_years
- 8.29
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.458
- G2M_CHECKPOINT+0.408
- SPERMATOGENESIS+0.270
- DNA_REPAIR+0.237
- MYC_TARGETS_V1+0.189
- MITOTIC_SPINDLE+0.170
- PANCREAS_BETA_CELLS+0.072
- PROTEIN_SECRETION+0.030
- PI3K_AKT_MTOR_SIGNALING-0.020
- HEME_METABOLISM-0.088
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.655
- INTERFERON_GAMMA_RESPONSE-0.599
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.589
- TNFA_SIGNALING_VIA_NFKB-0.542
- INFLAMMATORY_RESPONSE-0.523
- IL6_JAK_STAT3_SIGNALING-0.521
- ALLOGRAFT_REJECTION-0.504
- ANGIOGENESIS-0.501
- CHOLESTEROL_HOMEOSTASIS-0.499
- COAGULATION-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HTEPAKCM | medulloblastoma | — | 0.991 |
| 2 | BS_ERWT0ZWE | medulloblastoma | — | 0.985 |
| 3 | BS_KN92S7YQ | medulloblastoma | — | 0.981 |
| 4 | BS_J8G4SH4Z | medulloblastoma | — | 0.979 |
| 5 | BS_3NWQXPQV | medulloblastoma | — | 0.976 |
| 6 | BS_VMEX27TN | medulloblastoma | — | 0.975 |
| 7 | BS_2SFTWNVE | medulloblastoma | — | 0.974 |
| 8 | BS_61E80SD6 | medulloblastoma | — | 0.973 |
| 9 | BS_GNV89A5P | medulloblastoma | — | 0.971 |
| 10 | BS_4PH1MBGR | medulloblastoma | — | 0.971 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.458 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.408 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.237 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.189 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.072 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |